Equities analysts expect that DexCom, Inc. (NASDAQ:DXCM) will announce earnings per share (EPS) of $0.45 for the current quarter, Zacks reports. Nine analysts have issued estimates for DexCom’s earnings, with the lowest EPS estimate coming in at $0.23 and the highest estimate coming in at $0.62. DexCom reported earnings per share of $0.79 in the same quarter last year, which would suggest a negative year-over-year growth rate of 43%. The business is expected to issue its next earnings report on Tuesday, July 27th.
On average, analysts expect that DexCom will report full year earnings of $2.25 per share for the current fiscal year, with EPS estimates ranging from $1.87 to $2.61. For the next year, analysts forecast that the company will post earnings of $3.29 per share, with EPS estimates ranging from $2.68 to $3.85. Zacks’ EPS averages are an average based on a survey of analysts that cover DexCom.
DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 29th. The medical device company reported $0.33 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.31 by $0.02. DexCom had a return on equity of 27.29% and a net margin of 12.69%.
In other news, CAO Jereme M. Sylvain sold 600 shares of the company’s stock in a transaction on Wednesday, February 24th. The stock was sold at an average price of $404.00, for a total transaction of $242,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Nicholas Augustinos sold 1,875 shares of the company’s stock in a transaction on Tuesday, February 16th. The stock was sold at an average price of $412.03, for a total value of $772,556.25. Following the sale, the director now owns 806 shares of the company’s stock, valued at $332,096.18. The disclosure for this sale can be found here. Insiders sold a total of 39,727 shares of company stock valued at $14,784,421 over the last quarter. 0.69% of the stock is currently owned by insiders.
Several hedge funds have recently added to or reduced their stakes in the company. Baillie Gifford & Co. increased its holdings in shares of DexCom by 29.0% during the 4th quarter. Baillie Gifford & Co. now owns 5,453,844 shares of the medical device company’s stock worth $2,016,395,000 after buying an additional 1,225,388 shares during the last quarter. Sands Capital Management LLC increased its holdings in shares of DexCom by 28.2% during the 1st quarter. Sands Capital Management LLC now owns 2,936,502 shares of the medical device company’s stock worth $1,055,349,000 after buying an additional 645,568 shares during the last quarter. Lone Pine Capital LLC increased its holdings in shares of DexCom by 389.7% during the 4th quarter. Lone Pine Capital LLC now owns 2,267,809 shares of the medical device company’s stock worth $838,454,000 after buying an additional 1,804,722 shares during the last quarter. Artisan Partners Limited Partnership increased its holdings in shares of DexCom by 29.8% during the 1st quarter. Artisan Partners Limited Partnership now owns 1,967,829 shares of the medical device company’s stock worth $707,218,000 after buying an additional 451,362 shares during the last quarter. Finally, Brown Advisory Inc. increased its holdings in DexCom by 5.4% in the 4th quarter. Brown Advisory Inc. now owns 1,564,114 shares of the medical device company’s stock valued at $578,285,000 after purchasing an additional 79,666 shares in the last quarter. Institutional investors and hedge funds own 94.06% of the company’s stock.
Shares of NASDAQ:DXCM traded up $9.29 during trading on Monday, hitting $333.25. 804,799 shares of the stock were exchanged, compared to its average volume of 846,172. The company has a fifty day moving average price of $378.25 and a two-hundred day moving average price of $366.11. The company has a market cap of $32.23 billion, a PE ratio of 137.71, a P/E/G ratio of 6.15 and a beta of 0.86. The company has a current ratio of 6.39, a quick ratio of 6.00 and a debt-to-equity ratio of 1.10. DexCom has a 12-month low of $305.63 and a 12-month high of $456.23.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system.
Read More: Why are percentage decliners important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.